Gilead Sciences Inc (GILD)
Gilead Sciences Inc. is a biopharmaceutical company specializing in the development and commercialization of antiviral medicines. Founded in 1987, it is known for its innovative treatments for HIV/AIDS, hepatitis B and C, and other viral infections. Gilead has also expanded into oncology and inflammatory diseases, making significant contributions to advancing global healthcare through its research and development efforts.
Dividend History
Investors can expect a dividend payout of $0.79 per share, scheduled to be distributed in 9 days on September 29, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 29, 2025 | $0.79 | 2025-09-15 | 2025-09-15 |
| June 27, 2025 | $0.79 | 2025-06-13 | 2025-06-13 |
| March 28, 2025 | $0.79 | 2025-03-14 | 2025-03-14 |
| December 30, 2024 | $0.77 | 2024-12-13 | 2024-12-13 |
| September 27, 2024 | $0.77 | 2024-09-13 | 2024-09-13 |
Dividends Summary
- Gilead Sciences Inc has issued 42 dividend payments over the past 10 years
- The most recent dividend was paid 85 days ago, on June 27, 2025
- The highest dividend payed out to investors during this period was $0.79 per share
- The average dividend paid during this period was $0.64 per share.
Company News
Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, was recognized at the China Capital Market Development Forum for its exceptional performance. The company reported strong financial results, expanded its user base, and launched a proprietary AI Large Language Model for chronic disease management.
The biotech sector shows potential for significant growth by year-end, driven by anticipated Federal Reserve rate cuts and improving market conditions that could benefit rate-sensitive biotech stocks.
Kite Pharma, a Gilead Sciences subsidiary, acquired Interius BioTherapeutics for $350 million to expand its in vivo CAR T cell therapy capabilities, with the deal expected to slightly reduce 2025 earnings per share.
MacroGenics reported Q2 2025 financial results with revenue of $22.2 million, missing analyst expectations. The company is focusing on its research-stage pipeline and strategic partnerships while managing costs after exiting its previous marketed product.
Gilead Sciences (GILD) closed the most recent trading day at $69.61, moving -1.58% from the previous trading session.
